High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BACKGROUND: Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yinzong, Sun, Lunquan, Fu, Yongming, Huang, Yan, Zhou, Rongrong, Hu, Xingwang, Zhou, Pengcheng, Quan, Jun, Li, Ning, Fan, Xue-Gong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731191/
https://www.ncbi.nlm.nih.gov/pubmed/29246127
http://dx.doi.org/10.1186/s12885-017-3868-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731191/
https://www.ncbi.nlm.nih.gov/pubmed/29246127
http://dx.doi.org/10.1186/s12885-017-3868-2

Ejemplares similares